Imaging Oncogene Expression

Overview

Journal Eur J Radiol

Specialty Radiology

Date 2009 Mar 7

PMID 19264436

Citations 6

Authors

Archana Mukherjee

Eric Wickstrom

Mathew L Thakur

Affiliations

Soon will be listed here.

Abstract

This review briefly outlines the importance of molecular imaging, particularly imaging of endogenous gene expression for noninvasive genetic analysis of radiographic masses. The concept of antisense imaging agents and the advantages and challenges in the development of hybridization probes for in vivo imaging are described. An overview of the investigations on oncogene expression imaging is given. Finally, the need for further improvement in antisense-based imaging agents and directions to improve oncogene mRNA targeting is stated.

Citing Articles

Positron emission tomography molecular imaging-based cancer phenotyping.

Jin C, Luo X, Li X, Zhou R, Zhong Y, Xu Z Cancer. 2022; 128(14):2704-2716.

PMID: 35417604 PMC: 9324101. DOI: 10.1002/cncr.34228.

Application and Evaluation of [Tc]-Labeled Peptide Nucleic Acid Targeting in Breast Cancer Imaging.

Jiang Y, Gai Y, Long Y, Liu Q, Liu C, Zhang Y Mol Imaging. 2020; 19:1536012120916124.

PMID: 32559121 PMC: 7307583. DOI: 10.1177/1536012120916124.

Effects of hypoxanthine substitution in peptide nucleic acids targeting KRAS2 oncogenic mRNA molecules: theory and experiment.

Sanders J, Wampole M, Chen C, Sethi D, Singh A, Dupradeau F J Phys Chem B. 2013; 117(39):11584-95.

PMID: 23972113 PMC: 3946533. DOI: 10.1021/jp4064966.

Radiolabeled oligonucleotides for antisense imaging.

Iyer A, He J Curr Org Synth. 2011; 8(4):604-614.

PMID: 21822406 PMC: 3148791. DOI: 10.2174/157017911796117241.

Native mRNA antisense-accessible sites library for the selection of antisense oligonucleotides, PNAs, and siRNAs.

Fang H, Shen Y, Taylor J RNA. 2010; 16(7):1429-35.

PMID: 20498459 PMC: 2885691. DOI: 10.1261/rna.1940610.

References

Paroo Z, Corey D . Imaging gene expression using oligonucleotides and peptide nucleic acids. J Cell Biochem. 2003; 90(3):437-42. DOI: 10.1002/jcb.10626. View

DIncalci M . Correlation of ErbB2 gene status, mRNA and protein expression. Onkologie. 2006; 29(6):246-7. DOI: 10.1159/000093385. View

Sato N, Kobayashi H, Saga T, Nakamoto Y, Ishimori T, Togashi K . Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin Cancer Res. 2001; 7(11):3606-12. View

Tian X, Chakrabarti A, Amirkhanov N, Aruva M, Zhang K, Cardi C . Receptor-mediated internalization of chelator-PNA-peptide hybridization probes for radioimaging or magnetic resonance imaging of oncogene mRNAs in tumours. Biochem Soc Trans. 2007; 35(Pt 1):72-6. DOI: 10.1042/BST0350072. View

Lowy D, Willumsen B . Function and regulation of ras. Annu Rev Biochem. 1993; 62:851-91. DOI: 10.1146/annurev.bi.62.070193.004223. View

Roivainen A, Tolvanen T, Salomaki S, Lendvai G, Velikyan I, Numminen P . 68Ga-labeled oligonucleotides for in vivo imaging with PET. J Nucl Med. 2004; 45(2):347-55. View

Pepper C, Bentley P, Hoy T . Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1996; 95(3):513-7. DOI: 10.1046/j.1365-2141.1996.d01-1927.x. View

Gleave M, Monia B . Antisense therapy for cancer. Nat Rev Cancer. 2005; 5(6):468-79. DOI: 10.1038/nrc1631. View

Chakrabarti A, Zhang K, Aruva M, Cardi C, Opitz A, Wagner N . Radiohybridization PET imaging of KRAS G12D mRNA expression in human pancreas cancer xenografts with [(64)Cu]DO3A-peptide nucleic acid-peptide nanoparticles. Cancer Biol Ther. 2007; 6(6):948-56. DOI: 10.4161/cbt.6.6.4191. View

10.

Wickstrom E, Bacon T, Gonzalez A, Freeman D, Lyman G, Wickstrom E . Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci U S A. 1988; 85(4):1028-32. PMC: 279694. DOI: 10.1073/pnas.85.4.1028. View

11.

Tian X, Aruva M, Zhang K, Shanthly N, Cardi C, Thakur M . PET imaging of CCND1 mRNA in human MCF7 estrogen receptor positive breast cancer xenografts with oncogene-specific [64Cu]chelator-peptide nucleic acid-IGF1 analog radiohybridization probes. J Nucl Med. 2007; 48(10):1699-707. DOI: 10.2967/jnumed.107.042499. View

12.

Berns E, Klijn J, van Putten W, van Staveren I, Portengen H, Foekens J . c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res. 1992; 52(5):1107-13. View

13.

Jia F, Figueroa S, Gallazzi F, Balaji B, Hannink M, Lever S . Molecular imaging of bcl-2 expression in small lymphocytic lymphoma using 111In-labeled PNA-peptide conjugates. J Nucl Med. 2008; 49(3):430-8. DOI: 10.2967/jnumed.107.045138. View

14.

Revillion F, Bonneterre J, Peyrat J . ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998; 34(6):791-808. DOI: 10.1016/s0959-8049(97)10157-5. View

15.

Agrawal S . Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 1996; 14(10):376-87. DOI: 10.1016/0167-7799(96)10053-6. View

16.

Tian X, Aruva M, Qin W, Zhu W, Duffy K, Sauter E . External imaging of CCND1 cancer gene activity in experimental human breast cancer xenografts with 99mTc-peptide-peptide nucleic acid-peptide chimeras. J Nucl Med. 2004; 45(12):2070-82. View

17.

Mankoff D, Link J, Linden H, Sundararajan L, Krohn K . Tumor receptor imaging. J Nucl Med. 2008; 49 Suppl 2:149S-63S. DOI: 10.2967/jnumed.107.045963. View

18.

Amirkhanov N, Dimitrov I, Opitz A, Zhang K, Lackey J, Cardi C . Design of (Gd-DO3A)n-polydiamidopropanoyl-peptide nucleic acid-D(Cys-Ser-Lys-Cys) magnetic resonance contrast agents. Biopolymers. 2008; 89(12):1061-76. PMC: 2668199. DOI: 10.1002/bip.21059. View

19.

Merino M, Manrow R, Lawrence J, Bluth R, Wittenbel K, Simpson J . Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med. 1995; 1(12):1257-60. DOI: 10.1038/nm1295-1257. View

20.

Pellegata N, Sessa F, Renault B, Bonato M, Leone B, Solcia E . K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res. 1994; 54(6):1556-60. View